Q&A: 'toxic' effects of sugar: should we be afraid of fructose? by Tappy, L.
Fructose has recently been the focus of much 
interest as a possible contributor to the current 
epidemic of metabolic diseases. What is fructose, 
and why is it implicated in metabolic disease?
Fructose is a hexose with the same chemical formula, 
C6H12O6, as glucose. These two sweet-tasting molecules 
differ structurally, however, as fructose has a keto-group 
on the first carbon while glucose presents an aldehyde 
group on the second carbon. Free fructose, together with 
free glucose, is present in small amounts in fruits and 
honey. The main part of today’s dietary fructose intake 
comes from sucrose, a disaccharide composed of one 
molecule of glucose linked to a molecule of fructose 
through an alpha 1-4 glycoside bond.
The link with metabolic disease is partly circumstantial. 
Fructose consumption has been low throughout most of 
human history, but started to increase after the crusades, 
when Europeans became acquainted with sucrose 
produced from sugar cane in Asia. It was at first a luxury 
product, but consumption rapidly increased in the 16th 
and 17th centuries when sugar became more widely 
available as a consequence of colonial trading. Its 
consumption was boosted, first by the introduction of 
new beverages – tea, coffee, and cocoa in the 17th to 18th 
centuries; and second with the production of chocolate 
bars, ice-creams, and sodas at the beginning of the 20th 
century. Total sugar consumption thus increased from 
less than 5 kg/person/year in the 1800s to about 40 kg at 
the turn of the 19th century, and about 70 kg/person/year 
in 2006. In short, a rapid and continuous increase in 
consumption has been observed from 1750 until the 
present day.
In the 1960s, a novel food technology allowed the large-
scale, industrial conversion of glucose into fructose. As a 
result, the US corn industry started preparing what is 
now known as high fructose corn syrup (HFCS), that is, a 
concentrated solution of corn-derived glucose and 
fructose mixed in various relative proportions. Mainly 
because of its low cost, HFCS consumption replaced 
approximately one-third of the total sugar consumption 
in the USA between 1970 and 2000, paralleling to some 
extent the increasing prevalence of obesity during this 
period. Consequently, HFCS has been a particular focus 
of possible blame for the obesity epidemic. However, 
HFCS consumption has remained very low in other parts 
of the world where obesity has also increased, and the 
most commonly used form of HFCS contains about 55% 
fructose, 42% glucose , and 3% other sugars, and hence is 
associated with similar total fructose and glucose intakes 
as with sugar. Furthermore, sucrose is hydrolyzed in the 
gut and absorbed into the blood as free glucose and 
fructose, so one would expect HFCS and sucrose to have 
the same metabolic consequences. In short, there is 
currently no evidence to support the hypothesis that 
HFCS makes a significant contribution to metabolic 
disease independently of the rise in total fructose 
consumption.
So why the focus on fructose in particular?
Several reasons. First of all, fructose is not essential for 
any physiological function that we know of. This is in 
contrast to glucose, which is used by all cells in the body 
to generate energy and constitutes the nearly exclusive 
energy fuel for the brain. As a consequence of this largely 
exclusive reliance on glucose for brain metabolism, 
intricate hormonal and neural mechanisms have evolved 
to maintain a constant level of glucose in the blood.
We do not need to eat sugar to maintain blood glucose 
levels, however. Until relatively recently, our dietary 
source of glucose was derived from complex 
carbohydrates, principally from grains. Grains contain 
starch, which is a polymer of several thousands of glucose 
molecules linked together by alpha 1-4 glycosidic bonds, 
with occasional branching points due to alpha 1-6 
glycosidic bonds. Cooked starch can be readily digested 
by amylase produced by the salivary glands and pancreas, 
resulting in the formation of maltodextrins (small chains 
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of four to nine glucose molecules), maltose, isomaltose, 
or triomaltose in the gut lumen (Figure 1). These 
compounds are subsequently digested into glucose by 
brush border enzymes of the duodenum and jejunum. 
Ingestion of starchy products therefore provides a 
plentiful supply of glucose, which, upon absorption into 
the circulation, can be used as an energy source by most 
cells, or be stored as glycogen in the liver and in muscle.
With the exception of a limited amount of free glucose 
and fructose present in honey and fruits, grains and other 
starchy food have been the sole source of carbohydrate in 
the western diet for the major portion of man’s history. 
Sucrose is not only a non-essential dietary element, it has 
two undesirable consequences. First, because of its rapid 
digestion, it leads to surges in blood glucose that may 
place some stress on the homeostatic mechanisms 
mediated by insulin; and second, it introduces fructose, 
which we do not need and whose metabolism, when 
ingested in excessive amounts, imposes an important 
metabolic burden on the liver.
How do we metabolize fructose? Is it treated 
differently from glucose?
Yes it is. Glucose derived from fruits, sugar or digestion 
of starch is absorbed through the gut into the portal vein. 
A portion (15 to 30%) of glucose reaching the liver in this 
way is transported into hepatocytes by the membrane 
transporter GLUT2. Once in the cell, glucose is converted 
into glucose-6-phosphate under the control of gluco-
kinase, then into fructose 1-6 diphosphate through the 
action of phosophofructose kinase and finally to triose-
phosphate and pyruvate. Pyruvate can then be decarboxylated 
to acetyl coenzyme A, and enter the tricarboxylic acid cycle 
for ATP production. Intracellular ATP and citrate exert a 
negative feedback on phosphofructokinase, so that hepatic 
glucose catabolism is tuned to the energy status of the 
Figure 1. Digestion and absorption of starch and sugar. Starch is a polymer of several thousand molecules of glucose, which is digested by the 
pancreatic enzyme alpha-amylase into maltose, isomaltose, maltotriose (not represented in the figure) and maltodextrins. At the level of the brush 
border of the intestinal mucosa, specific enzymes generate glucose from maltose (sucrase, maltase), isomaltose (isomaltase) and maltodextrins 
(glucoamylase). Glucose is then absorbed into the enterocyte by an apical co-transport with NaCl (Sodium-glucose-transporter-1, SGLT1) and 
transferred to the blood at the basolateral membrane through a facilitated transport mediated by GLUT2. Sucrose is cleaved into glucose and 
fructose by sucrase at the brush border. Fructose is transported into the enterocyte independently of Na by GLUT5, and due to the presence of 
fructose metabolizing, gluconeogenic and lipogenic enzymes, part of the absorbed fructose may be metabolized to lactate, glucose, and fatty 
acids within the enterocytes. Unmetabolized fructose is transferred to the blood at the basolateral membrane by GLUT2.
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liver cells, and insulin regulates glucokinase expression 
and the activity of key glycolytic enzymes. Thus, in liver 
cells, as in other cells of the body, the breakdown of 
glucose is matched to meet energy requirements.
By contrast, fructose metabolism is not tuned to energy 
needs. A limited amount of fructose may be metabolized 
within the gut enterocytes, but for the most part it is 
absorbed through the gut into the portal vein. As with 
glucose, it is transported into hepatocytes by GLUT2. 
However, once inside the hepatocyte, it is very rapidly 
converted into fructose-1-phosphate under the action of 
fructokinase, and then to triose-phosphate under the 
action of aldolase B. These two enzymes act specifically 
on fructose and fructose-1-phosphate, respectively, and 
are regulated neither by insulin nor by the energy status 
of the cell. As a consequence most fructose in portal blood 
is rapidly converted into triose-phosphate in hepatocytes. 
This leads to 1) a high consumption rate of hepatic ATP 
for the initial phosphorylation of fructose, which can lead, 
when fructose intake is high, to transient ATP depletion, 
formation of AMP and degradation of adenosine to uric 
acid; 2) an overflow of triose-phosphates, which are 
secondarily converted into lactate or glucose to be 
released into the circulation; 3) stimulation of glycogen 
synthesis; and 4) stimulation of the synthesis of fatty 
acids from the carbons of fructose, through a metabolic 
pathway known as de novo lipogenesis (Figure 2).
Are there harmful consequences of these features 
of fructose metabolism?
At a high level of intake, yes, and one of these is increased 
cardiovascular risk. Paradoxically this in part came to 
light because of a strong interest, in the 1980s, in the use 
of pure fructose as a sweetener for type 2 diabetic 
patients. This was proposed on the grounds that fructose 
might be less harmful than sucrose or glucose because, 
unlike glucose, it causes little hyperglycemia after eating 
(postprandial hyperglygemia), and is metabolized 
independently of insulin. Furthermore, it enhances 
energy expenditure compared to similar doses of glucose, 
which was thought to help prevent weight gain.
However, many short-term studies showed that 
substituting fructose for starch in the diet of type 2 
diabetic patients was associated with an increase in 
plasma triglyceride concentrations (both fasting and 
postprandial), raising the possibility that any beneficial 
effect on glycemic control may be counterbalanced by 
pro-atherogenic effects of hypertriglyceridemia.
If everyone’s liver cells, not just those of type 2 
diabetes patients, make triglycerides, couldn’t this 
also be a hazard for healthy people?
Yes. In healthy subjects, short-term overfeeding studies 
with large doses of fructose (in the 1.5 to 3  g/kg/day, 
corresponding to 15 to 30% total energy requirement) 
have repeatedly reported an increase in fasting and 
postprandial triglycerides, mainly associated with very 
low density lipoproteins (VLDLs), and an increase in 
concentrations of apoB100 (a component of both VLDLs 
and low-density lipoproteins (LDLs)). Circulating VLDL-
triglycerides are significantly associated with cardio-
vascular disease, so this would indicate increased 
cardiovascular risk associated with fructose.
Two main mechanisms may account for this effect. 
First, fructose stimulates hepatic de novo lipogenesis, 
thus contributing additional fatty acids for hepatic 
triglyceride synthesis, as mentioned earlier. The amount 
of newly formed fatty acid synthesized from fructose 
remains small, however. But second, fructose ingestion 
acutely decreases VLDL-triglyceride (VLDL-TG) clearance 
in adipose tissue, thus increasing VLDL-TG residence 
time in the blood. An increase in plasma triglyceride 
concentration has been generally observed with 
hypercaloric, high fructose diets, that is, when fructose is 
associated with excess total energy intake. There is, 
however, evidence that fructose increases fasting 
triglyceride even when total energy intake is calculated to 
match energy requirements.
Moreover, there is strong evidence that 24-hour 
triglyceride concentration is an independent risk factor 
for atherosclerosis. In addition, a high plasma VLDL-
triglyceride concentration leads to the generation of 
smaller, more dense LDL particles through the 
cholesteryl-ester mediated transfer of lipids between 
VLDL and LDL particles. This process is further 
enhanced in fructose-induced hypertriglyceridemia, 
probably because of the impaired VLDL-TG clearance, 
and hence an increased residence time of VLDL in the 
blood. Both fructose and sucrose therefore lead to an 
Figure 2. Metabolism of fructose in the liver. The majority of 
fructose in the portal vein is taken up by the liver to be converted 
into glucose, glycogen, and lactate. A small portion may be either 
oxidized within hepatocytes or converted into fatty acid, which 
will be either secreted as very low density lipoprotein-triglyceride 
(VLDL-TG) particles or stored as intrahepatocellular lipids (IHCL). 
Only a minor portion escapes liver uptake and reaches the systemic 
circulation; blood fructose concentrations therefore remain very low 
even after ingestion of a large fructose load.
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increased proportion of small dense LDL particles within 
the LDL fraction, a phenotype that is clearly associated 
with an increased cardiovascular risk.
In parallel, animal experiments revealed that rodents 
on a high sucrose or high fructose diet almost invariably 
develop obesity, insulin resistance and diabetes, 
dyslipidemia, and even occasionally high blood pressure, 
the characteristic features of metabolic syndrome, which 
also together increase the risk of cardiovascular disease. 
Furthermore, these adverse metabolic effects have been 
shown to be largely attributable to the fructose component 
of sucrose. One must recognize, however, that feeding 
animals a high-fat diet leads to similar metabolic 
alterations, and that energy excess from any food source 
may be the critical factor responsible for metabolic 
alterations.
If high fructose intake can be responsible 
for the development of obesity and the 
associated metabolic disorders that constitute 
metabolic syndrome, wouldn’t this show up in 
epidemiological studies?
The answer to this question is not straightforward. 
Several large cohort studies have included a dietary 
evaluation and a medical follow-up, but their 
interpretation is problematic, for several reasons. First, 
until recently, fructose as such did not appear in 
nutritional databases, and these studies therefore looked 
at a variety of different variables, some evaluating the 
effects of calculated total sugar intake, others the effects 
of calculated fructose intake, while others examined the 
effects of specific food groups (sugar-sweetened 
beverages, sweets) that contribute substantially to total 
fructose intake. Second, the results vary according to 
how statistical analyses were performed. On one hand, 
some studies used a statistical analysis that was not 
adjusted for total energy intake, and documented a 
positive correlation with obesity. Some of these same 
studies, however, reported that obesity was associated 
not only with sugar-sweetened beverages and sweet 
intakes, but also with the consumption of potatoes and 
meat. On the other hand, some investigators argued that, 
in order to conclude that fructose (or sugar) is a major 
determinant of obesity, it is necessary to establish a 
positive correlation that is independent of total energy 
intake. These studies searched for a relationship between 
obesity and sugar intake expressed as a percentage of 
total calorie intake and generally failed to observe a 
significant positive correlation, or even reported a 
negative correlation. Furthermore, although these studies 
reported that the incidence of diabetes, dyslipidemia, 
liver disorders, or high blood pressure correlated 
positively with sugar intake, these relationships were no 
longer observed after adjusting for total body weight.
You say it’s hard to distinguish effects of fructose 
on obesity from effects of any excess eating – could 
fructose just be encouraging us to eat more?
Yes. Rodents fed ad libitum a high-sucrose or a high-
fructose diet invariably increase their body weight and 
body fat mass because of an increased total energy intake. 
This may be due to a stimulation of sweet receptors in the 
mouth activating reward pathways within the brain.
Alternatively, ingestion of fructose or sucrose may elicit 
lower satiety responses than other nutrients. Satiety is a 
process through which eating sends signals that activate 
specific brain pathways that in turn regulate appetite. 
Protein and carbohydrate have long been known to elicit 
a robust satiety response, mediated in part by an increase 
in insulin. Some observations suggest that fructose or 
sugar exert less satiating effects than starch or glucose. 
Possibly due to a lower insulin response. In humans, 
there is evidence that a meal containing 30% energy as 
fructose, compared with a similar meal containing 30% 
glucose, elicits lower postprandial concentrations of 
glucose, insulin and leptin, and higher concentrations of 
ghrelin in the blood. Since high blood glucose, insulin 
and leptin are known as satiating signals to the brain, 
while ghrelin stimulates food intake, one would expect 
that fructose would indeed exert lower satiating effects 
than other carbohydrates. The significance of this has not 
been demonstrated in practice, however, and several 
small studies assessing the satiety induced by meals with 
various glucose:fructose ratios did not present 
compelling evidence that fructose and sucrose are less 
satiating than other foods. A recent meta-analysis quite 
expectedly demonstrated that fructose intake leads, over 
short periods, to an increase in body weight when 
consumed as part of a high-calorie diet, but not as part of 
an energy balanced diet. This reminds us that body 
weight is strictly dependent on energy balance, and that, 
if anything, fructose would increase body weight through 
an increase in total energy intake.
Obesity is clearly associated with metabolic disease, 
but not all fat deposits are equal in this respect. Fat stored 
within the abdominal cavity, that is, visceral fat, is much 
more closely associated with cardiovascular diseases than 
subcutaneous fat. It has been proposed, based on one 
single study, that fructose associated with excess energy 
intake would preferentially increase visceral fat. This 
needs to be confirmed in larger, well controlled studies, 
however.
What about other aspects of metabolic syndrome? 
Is fructose implicated in increased fat storage in 
the liver and for the development of non-alcoholic 
fatty liver disease?
Overfeeding with 30% energy as fructose nearly doubles 
intrahepatic fat content in healthy volunteers within a 
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few days. However, overfeeding with lesser amounts of 
fructose fails to enhance intrahepatic fat significantly, 
even when exposure is sustained for 4 weeks. Whether 
fructose exposure of longer duration would lead to 
continuous, more important deposition of intrahepatic 
fat and clinical hepatic steatosis (fatty liver) remains 
presently unknown. No large epidemiological study has 
evaluated the relationship between fructose or sucrose 
intake and non-alcoholic fatty liver disease (NAFLD) so 
far, so the suspicion that fructose may be deleterious for 
liver cells rests mainly on animal experiments. There are 
indeed observations, in animal models, that suggest 
fructose may promote hepatic inflammation and fibrosis, 
and hence may possibly play a role in the progression of 
NAFLD to non-alcoholic steatohepatitis (NASH).
And insulin resistance, could high fructose intake 
be a cause of this?
Insulin concentration increases after a meal, and is 
instrumental in maintaining adequate glucose concentra-
tions. It works by stimulating glucose uptake in skeletal 
muscle and adipose cells, increasing glucose oxidation to 
generate energy in the form of ATP, and favoring the 
storage of lipids in adipose tissue. In many obese subjects, 
and more particularly so in subjects with abdominal 
obesity, these effects of insulin are blunted, resulting in 
post-prandial hyperglycemia and hyper lipemia in spite of 
a normal or even increased insulin secretion. This 
alteration of insulin’s effect, known as insulin resistance, 
is a major factor responsible for hyper glycemia in type 2 
diabetes mellitus, and a prominent feature of metabolic 
syndrome. The mechanisms remain incompletely under-
stood, but accumulation of tri glyceride inside hepatocytes 
and muscle fibers, generating toxic intracellular lipid 
metabolites, is known to be involved.
In rodents fed high fructose diets, hyperglycemia and 
insulin resistance develop, but occur concomitantly with 
obesity, and hence the effects of fructose per se and those 
linked to excess body fat mass cannot be easily 
distinguished. There is evidence, however, that hepatic 
insulin resistance, characterized by increased fasting 
glucose production and impaired postprandial suppression 
of glucose output, occurs early after exposure to fructose, 
before important changes in body composition occur.
In humans, short-term overfeeding with 20 to 30% 
extra energy provided as fructose leads to a slight 
increase in fasting plasma glucose, and to a moderate 
(approximately 10%) increase in fasting glucose 
production, indicating some impairment of hepatic 
insulin sensitivity. These changes occur rapidly, within 
the first week after fructose exposure. There is, however, 
no detectable decrease in glucose disposal rate induced 
by insulin when measured by euglycemic 
hyperinsulinemic clamps (the most reliable method for 
measuring insulin resistance), indicating no significant 
whole body insulin resistance. In overweight subjects, 
fructose overfeeding for 10 weeks led to a modest 1 to 
3 kg body weight gain and significantly increased 
postprandial blood glucose and insulin concentrations, 
but the average blood glucose concentration barely 
reached the 2-hour postprandial value of 140 mg/dl, 
which corresponds to an impaired glucose tolerance. 
Based on the absence of directly documented insulin 
resistance, and the modest changes in glycemia and 
insulinemia observed even after very high fructose intake 
over several weeks, it appears that fructose per se is 
unlikely to be responsible for important alterations of 
glucose homeostasis.
One cannot, however, discard the hypothesis that 
longer exposure to high fructose intake may be associated 
with insulin resistance, possibly secondary to increased 
body fat mass. In addition, a number of mechanisms that 
could theoretically lead to insulin resistance have 
emerged from animal or in vitro experiments. Specifically, 
fructose has been shown to cause uric acid-mediated 
inhibition of endothelium-dependant vasodilation, to 
impair insulin signaling secondary to oxidative stress, to 
stimulate hepatic and extra-hepatic inflammation and 
fibrosis, and to induce lipotoxicity in skeletal muscle 
(Figure 3). Further studies will be required to evaluate 
whether these mechanisms may be responsible for the 
development of insulin resistance in humans with years-
long exposure to fructose.
How much fructose do you have to consume to see 
adverse effects?
One recent meta-analysis of several small trials in healthy 
volunteers indicated that fasting and postprandial 
triglyceride concentrations were increased with intake 
higher than 100 g and 50 g/day, respectively (corresponding 
to sucrose intake of 200 and 100 g/day). In an average 
non-obese individual with moderate physical activity, 
this corresponds to 15 to 20% and 7.5 to 10%, respectively, 
of total daily energy intake. Another meta-analysis of 
studies in which fructose was substituted for starch in the 
diet of type 2 diabetic subjects indicated that plasma 
triglyceride concentrations were increased for fructose 
intakes higher than 60 g/day. However, even with moderate 
amounts of fructose (40 g/day) that do not change fasting 
plasma triglycerides, one can observe a shift from large to 
more atherogenic small, dense LDL particles.
Is the average consumption of sugar worldwide 
dangerous?
Consumption of sugar is about 100 to 150  g/day in 
America, Europe, and Oceania (with important regional 
differences), corresponding to 50 to 75 g of fructose daily. 
Since these are averages for the whole population, it 
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means that probably about half of the population has a 
daily consumption in excess of these figures, and may 
thus be possibly exposed to fructose-induced 
dyslipidemia. In the USA, the average consumption of 
fructose, calculated from the National Health and 
Nutritional Examination Survey III data, was 55 g/day for 
the whole population. In adults, however, 10% of the 
population was consuming more than 15% of their daily 
energy intake as fructose. Thus, while the major portion 
of the population may have innocuous fructose intake, a 
small but still significant portion of the population may 
be exposed to high, potentially deleterious intakes.
Is everybody at the same risk of developing 
dyslipidemia and metabolic diseases from a high 
fructose intake?
This important question remains unanswered at present, 
though there are indications that the answer will be ‘no’. It 
is well known that athletes and individuals involved in 
strenuous physical activity often have high sugar 
consumption, but as a group have less metabolic and 
cardiovascular disease than sedentary subjects. A recent 
study conducted by my laboratory finds that with daily 
exercise, high fructose consumption does not increase 
plasma triglyceride concentration. Short-term fructose 
overfeeding has been shown to cause less dyslipidemia in 
pre-menopausal women than in men (and no change in 
hepatic insulin sensitivity). Physical activity, gender, and 
possibly ethnic or genetic factors may therefore modulate 
the health effects of fructose. For athletes, a high fructose 
intake may even be beneficial, as it has been shown that 
fructose can be metabolized during exercise, and increase 
performance.
How might that work?
Athletes frequently use foods and drinks rich in rapidly 
absorbed carbohydrate during exercise to provide a 
continuous energy substrate to the working muscle. 
Lactic acid produced from fructose can be oxidized by 
the working muscle, and hence moderate amounts of 
fructose consumed together with glucose during exercise 
can increase total carbohydrate oxidation and may 
improve physical performance. Since fructose is known 
to cause a larger synthesis of hepatic glycogen than 
glucose, its presence in the diet before and after exercise 
may also be beneficial to ensure high hepatic glycogen 
stores.
On the available evidence, is it time for public 
health action?
That question cannot be definitively answered on the 
basis of the available evidence. A high fructose diet, 
consumed by sedentary individuals, consistently increases 
hepatic VLDL-TG secretion through stimulation of de 
novo lipogenesis in the liver and decreased extrahepatic 
VLDL-TG clearance. It also alters LDL particle size, thus 
leading to alterations of the lipid profile known to be 
associated with increased cardiovascular diseases. These 
alterations are, however, observed only at very high levels 
of fructose intake. In contrast, even at high doses, 
fructose produces only modest alterations of glucose 
homeostasis. Fructose indisputably alters hepatic glucose 
production, but with little impact on blood glucose 
concentrations, and does not alter whole body insulin 
sensitivity independently of body weight changes.
But major questions remain to be addressed before we 
have a clear idea of the role of fructose in metabolic 
diseases.
So what do we still need to know?
First, it is not clear whether fructose consumption leads 
to increased total energy intake and obesity. To address 
this question further studies focusing on the effects of 
fructose on food intake control will be needed, and the 
possibility that fructose may increase energy intake 
through mechanisms related to addiction will need to be 
assessed. We also need to assess whether interventions 
aimed at reducing fructose intake in overweight subjects, 
Figure 3. Putative mechanisms that may link excessive fructose 
intake to the development of metabolic disorders in the long 
term. Stimulation of hepatic de novo lipogenesis may lead to the 
deposition of fat within the liver, which may secondarily be involved 
in hepatic insulin resistance. Hepatic de novo lipogenesis may also 
cause an increase in VLDL-TG secretion and ectopic deposition of 
lipids in skeletal muscle, and contribute to muscle insulin resistance 
through the generation of muscle lipid metabolites. Fructose 
metabolism in the liver increases uric acid synthesis, and the ensuing 
hyperuricemia can secondarily be responsible for endothelial cell 
dysfunction, impaired insulin-induced vasodilation and a consequent 
failure to increase muscle blood flow after a meal, leading to muscle 
insulin resistance. In addition, the metabolism of fructose in liver cells 
can cause the formation of reactive oxygen species (ROS), which 
can activate nuclear factor (NF)kB, causing inflammation-linked 
insulin resistance. Finally, fructose can increase the translocation of 
bacterial endotoxin (lipopolysaccharide (LPS)) into the portal blood, 
causing endotoxin-mediated stimulation of inflammation. TNF, tumor 
necrosis factor.
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by whatever means, will efficiently reduce body weight 
and cardiovascular and metabolic risk factors. Such 
studies are obviously needed before implementing 
litigation or policies aimed at reducing consumption of 
sugars at the population level.
Second, we do not know whether fructose causes 
insulin resistance and diabetes mellitus in the long term. 
Even with very high fructose supplementation, there is 
only a modest alteration of hepatic glucose metabolism, 
which may merely represent a metabolic adaptation to 
the consumption of a glycogenic substrate rather than a 
step toward diabetes. There are, however, a number of 
plausible mechanisms documented in animal studies that 
may lead to deterioration of glucose homeostasis in the 
long term. We will need more basic and clinical studies to 
better evaluate whether these data are relevant to human 
health.
Finally, we need a better understanding of the genetic 
and environmental factors in the effect of fructose 
consumption. There is good evidence that pre-
menopausal women and physically active males and 
females may be resistant to the adverse metabolic effects 
of fructose, and it can by hypothesized that other sub-
groups of individuals may have enhanced responsiveness 
and would benefit from a dietary restriction. To address 
this question, we need comparative studies of fructose’s 
effects in populations at increased risk of developing 
metabolic diseases, such as offspring of subjects with 
type 2 diabetes, overweight individuals, insulin-resistant 
subjects, or ethnic groups with a high incidence of 
metabolic diseases.
So what can we conclude?
There is clearly cause for immediate concern regarding 
potential long-term effects of very high fructose intake in 
patients with metabolic disorders and in subjects already 
at risk of developing metabolic disease due to overweight 
or low physical activity. Given the substantial 
consumption of fructose in our diet, mainly from 
sweetened beverages, sweet snacks, and cereal products 
with added sugar, and the fact that fructose is an entirely 
dispensable nutrient, it appears sound to limit 
consumption of sugar as part of any weight loss program 
and in individuals at high risk of developing metabolic 
diseases. There is no evidence, however, that fructose is 
the sole, or even the main factor in the development of 
these diseases, nor that it is deleterious to everybody, and 
public health initiatives should therefore broadly focus 
on the promotion of healthy lifestyles generally, with 
restriction of both sugar and saturated fat intakes, and 
consumption of whole grains, fresh fruits and vegetables 
rather than focusing exclusively on reduction of sugar 
intake.
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